Sanofi Selects Recursion Immunology Drug Candidate for Development
Sanofi has optioned the first development candidate from its research collaboration with Recursion, adding it to its development pipeline. The potential first-in-class oral small molecule, developed using AI-enabled design, targets a challenging pair of targets implicated in inflammatory disease. Phase 1 trials are exp